<i>ESR1</i> F404 Mutations and Acquired Resistance to Fulvestrant in <i>ESR1</i> -Mutant Breast Cancer

Belinda Kingston(Breast Cancer Now), Nicholas C. Turner(Institute of Cancer Research)

Cancer Discovery

November 17, 2023

10.1158/2159-8290.cd-22-1387

Cited by 35

Related Papers

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

|The Lancet Oncology|2016|1.8k

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

|New England Journal of Medicine|2015|1.6k

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

|Annals of Oncology|2021|1.4k

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

|New England Journal of Medicine|2018|1.3k

Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review

|Journal of Clinical Oncology|2018|925